Chasing Cures. Delivering Hope™
Translating groundbreaking science and precision delivery into potentially life-changing medicines for people living with FTD and ALS.
WELCOME TO AVIADOBIO
At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into potentially life-changing medicines for people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
With our deep understanding of the brain and our suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to potentially halt or potentially even reverse neurodegenerative diseases.
pioneering research
Our research focus is on targeted and precise drug delivery and dosing for maximal biodistribution to the brain and spinal cord with a favorable safety profile. We believe delivery to be the game changer in overcoming challenges with existing treatment pathways.
AviadoBio was formed based on pioneering research from King’s College London and the UK Dementia Research Institute.
Starting from a promise…
“Our motivation is to fulfill a promise given to a generation of patients for whom there were no effective treatments but who shared their experiences and bodies so that we could find cures to treat their children.”
Prof. Chris Shaw
Chief Scientific and Clinical Advisor/Co-Founder
AN UNMET MEDICAL NEED
Frontotemporal dementia (FTD) and other neurodegenerative diseases like Alzheimer’s disease and amyotrophic lateral sclerosis (ALS) are depriving people of the prime years of their lives and have a devastating impact on families and loved ones. Few to no treatments exist for many of these neurodegenerative diseases despite many decades of research.
Recent progress and successes in genetic medicine have demonstrated its great promise in treating previously untreatable, life-threating neurological diseases.
Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to potentially halt or potentially even reverse neurodegenerative diseases. We deliver our gene therapies directly to the central nervous system where we believe they will provide the most benefit to patients.
About Us
Join Us
Our Science
A Phase 1/2 open-label clinical study to evaluate the safety and preliminary efficacy of AVB-101 in people with a genetic sub-type of frontotemporal dementia (FTD-GRN) is now open for enrollment.
